Literature DB >> 31187526

Multiple myeloma: Every year a new standard?

S Vincent Rajkumar1.   

Abstract

The treatment of myeloma is rapidly evolving. This article reviews the current diagnostic criteria, risk stratification, and approach to treatment of multiple myeloma. Treatment approach for both newly diagnosed and relapsed disease are discussed.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  myeloma; prognosis; therapy

Mesh：

Year:  2019        PMID： 31187526      PMCID： PMC6570407          DOI： 10.1002/hon.2586

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


  7 in total

1.  Progress in Myeloma - A Monoclonal Breakthrough.

Authors:  S Vincent Rajkumar; Robert A Kyle
Journal:  N Engl J Med       Date:  2016-10-06       Impact factor: 91.245

2.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

Review 3.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

4.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

5.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

Review 6.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

7.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528
  7 in total
  36 in total

1.  PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.

Authors:  Biao Xu; Jingyuan Li; Dehong Xu; Qijie Ran
Journal:  Ir J Med Sci       Date:  2022-05-04       Impact factor: 1.568

2.  Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.

Authors:  Julia Hambach; William Fumey; Tobias Stähler; Anna Josephine Gebhardt; Gerhard Adam; Katja Weisel; Friedrich Koch-Nolte; Peter Bannas
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

3.  Hypercalcaemia, Renal Dysfunction, Anaemia, Bone Disease (CRAB Criteria): A Case of Lymphoma.

Authors:  Balraj Singh; Pooja Gogia; Parminder Kaur; Nirmal Guragai; Michael Maroules
Journal:  Eur J Case Rep Intern Med       Date:  2020-12-21

4.  Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Authors:  Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff
Journal:  Eur J Haematol       Date:  2021-11-15       Impact factor: 3.674

5.  The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.

Authors:  Lisa J Crawford; David C Campbell; Jonathan J Morgan; Michelle A Lawson; Jennifer M Down; Dharminder Chauhan; Roisin M McAvera; Treen C Morris; Claudia Hamilton; Aswini Krishnan; Krishnaraj Rajalingam; Andrew D Chantry; Alexandra E Irvine
Journal:  Oncogene       Date:  2020-06-10       Impact factor: 9.867

Review 6.  Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Authors:  Fabio Morandi; Mahboubeh Yazdanifar; Claudia Cocco; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-07-22       Impact factor: 6.600

Review 7.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

8.  Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  JingSong He; XiaoYan Yue; DongHua He; Yi Zhao; Yang Yang; GaoFeng Zheng; Enfan Zhang; XiaoYan Han; WenJun Wu; Li Yang; Jing Chen; Zhen Cai
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

Review 9.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

10.  Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.

Authors:  Jing Li; Li Bao; Zhongjun Xia; Sili Wang; Xin Zhou; Kaiyang Ding; Wenhao Zhang; Wei Yang; Bingzong Li; Chengcheng Fu; Bing Chen; Luoming Hua; Liang Wang; Jun Luo; Yang Yang; Tianhong Xu; Weida Wang; Yun Huang; Guolin Wu; Peng Liu
Journal:  Ann Hematol       Date:  2020-09-06       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.